Overview
Substrate Bio operates AI-native data-production infrastructure for biology, connecting computational models with real-world experimentation. The company runs a network of autonomous, robotics-powered wet labs, starting in London with a second planned for San Francisco, running standardized experiments with full provenance, metadata, and quality control. Researchers access the labs via API, submitting experiment parameters and receiving structured data and metadata, while foundation models help design assay selections, cell systems, and gene panels. What sets Substrate Bio apart is its closed feedback loop, where better data improves its models and better models design better experiments. The goal is to make biological experimentation as programmable and scalable as computation itself.
Work here?Claim your company
Simplify's take
What believers are saying
- June 2026 jobs show ten openings, confirming active buildout and capital deployment.
- The company targets foundation-model labs and pharma, both high-spending biology buyers.
- Government grants plus venture funding reduce dilution while financing expensive lab infrastructure.
What critics are saying
- Substrate still lacks disclosed investors, revenue, and funding size after 2026 jobs.
- Execution hinges on hiring 32 people by Q1 2027 across London and San Francisco.
- If the first node underperforms, Series A conversion stalls and the platform thesis breaks.
What makes Substrate Bio unique
- Substrate Bio is building autonomous wet labs, not a CRO or cloud lab.
- King’s Cross launches integrated workcells and two scientific verticals by mid-2027.
- It combines foundation-model partnerships with physical experiment production and provenance tracking.
Help us improve and share your feedback! Did you find this helpful?